Wide Open Agriculture

14 September 2026

WOA SIGNS THREE ADDITIONAL FRAMEWORK AGREEMENTS

Highlights:

- *WOA has signed three additional non-binding framework agreements to advance the contract manufacturing pathways for its proprietary lupin-based ingredients.*

- *The signings build on the framework agreement announced on 10 August 2026, taking WOA to a total of four prospective contract manufacturing partners across Vietnam, India and Indonesia.*

- *Progressing multiple framework agreements in parallel enables WOA to protect its intellectual property while assessing technical and commercial feasibility across prospective manufacturing partners.*

- *Terms are broadly consistent across agreements and are non-binding, other than the intellectual property, restraint and confidentiality provisions.*

- *Intellectual property protections are binding and enforceable and continue for five years beyond termination of any agreement.*

- *Further framework agreements may follow as WOA works toward securing a preferred long-term manufacturing partner.*

Wide Open Agriculture Ltd (ASX: WOA) ("WOA" or "the Company") is pleased to confirm it has signed three further non-binding framework agreements for contract manufacturing of its lupin-based ingredients: with **Vietnam LifeScience Company Limited (VLS)**, a plant protein manufacturer based in Dong Nai Province, Vietnam; with **Shree Ram Agro Products, operating as OMN9 (OMN9)**, a plant protein manufacturer based in India; and with **PT Haldin Pacific Semesta (Haldin)**, a natural ingredients manufacturer based in West Java, Indonesia.

Each agreement protects WOA's intellectual property and sets out principles for a future Contract Manufacturing Agreement covering WOA's lupin-based ingredients.

These agreements continue the approach established by the framework agreement signed and announced on 10 August 2026, and take WOA to a total of four prospective contract manufacturing partners, each engaged on broadly consistent terms.

Together they represent further progress on WOA's strategy of shifting to a lower cost, capital-light contract manufacturing model, managing the risk and timeline for selection of its long-term manufacturing partner by progressing multiple candidates in parallel to technical and commercial feasibility study stage.

A structured partner selection process

As previously disclosed, WOA has identified more than 95 potential manufacturers, signed more than 12 non-disclosure agreements, and is negotiating framework agreements with a small number of shortlisted prospective partners.

Framework agreements with each candidate safeguards WOA's intellectual property during detailed technical assessments, commercial feasibility evaluations and potential production trials. This ensures proprietary assets remain protected before and after negotiating a final commercial agreement with a preferred partner.

These framework agreements are an important milestone in the structured selection of process rather than a series of commercial commitments. Additional framework agreements are likely to be signed as part of this process.

About VLS

VLS operates a dedicated pea protein manufacturing facility, located in the Bau Xeo Industrial Park in Dong Nai Province, Vietnam. Drawing on more than 30 years of pea protein expertise within its team, VLS manufactures premium plant protein for supplement, nutrition and food brands internationally, using a low-waste, closed-loop production approach. VLS's protein isolate manufacturing capability, technical resources and export orientation are directly relevant to WOA's lupin platform. Vietnam's extensive trade access into international markets supports WOA's objective of securing an Asia-based manufacturing base to supply its global customer base.

About OMN9

OMN9 is an Indian plant protein producer specialising in mung bean protein isolate and mung bean starch, with operations in Jodhpur, Rajasthan and in Delhi. OMN9 supplies clean-label, plant protein ingredients to food, beverage and nutraceutical customers, and brings established protein isolate manufacturing capability and technical resources relevant to WOA's lupin-based ingredients.

About Haldin

Haldin is an Indonesian natural ingredients manufacturer based in Cibitung, Bekasi, West Java. Haldin operates multiple production facilities in Indonesia, including liquid and powder extraction plants, a coconut processing facility and a materials preparation centre, and supplies natural extracts, essences, spray-dried powders and functional ingredients to food, beverage, nutraceutical, flavour and fragrance and cosmetic customers internationally.

WOA Chief Executive Officer Craig Swan said:

> *"Signing three further framework agreements shows our partner selection process is progressing. With intellectual property protections now in place with highly respected manufacturers across three countries, we can complete technical and commercial feasibility work in parallel. This allows WOA to progress our strategy of manufacturing our lupin ingredients at scale under contract manufacturing. Our approach manages risk for WOA and ensures we move forward with speed. We have already established each candidate as a successful and impressive business in their own right, and they each have interest and capability to engage with WOA to progress our strategy together. In the future we intend to progress to the stage of a definitive agreement with the partner best suited to scale our lupin ingredients."*

Framework Agreement Details

The terms of all three agreements are broadly consistent with the framework agreement from 10 August 2026. Each agreement covers all products derived from lupins. The intellectual property protections are binding and enforceable and remain in force for five years beyond the term of any agreement, a milestone WOA requires before sharing detailed technical information with a prospective manufacturing partner.

Each manufacturer may not produce lupin-based products for itself or any third party during the term of the agreement and for five years after its termination, nor use WOA's processes, know-how or technical information for any purpose other than manufacturing for WOA.

Other than these protections, and provisions relating to confidentiality, costs, governing law and dispute resolution, each agreement is non-binding, and neither party has a claim against the other if a definitive commercial agreement is not executed.

VLS: Conditional exclusivity - once VLS has completed commercial production of more than 50 tonnes of lupin protein isolate, VLS will become WOA's exclusive manufacturer of lupin ingredients for a period ending five years from the date of the agreement, provided VLS continues to accept WOA's firm purchase orders and meets production targets in line with WOA's rolling forecasts; otherwise, WOA's exclusivity obligations terminate. The parties have also agreed to explore potential joint venture opportunities to manufacture large-scale commercial quantities of lupin protein, lupin fibre and lupin oil.

OMN9: The parties will also discuss potential joint venture opportunities to manufacture large-scale commercial quantities of lupin protein and co-products in India.

A summary of the key provisions of each term sheet is set out in the Schedule below.

	VLS	**OMN9**	**Haldin**
Parties	Wide Open Agriculture Ltd (WOA) and Vietnam LifeScience Company Limited of Bau Xeo Industrial Park, Dong Nai City, Vietnam (VLS).	Wide Open Agriculture Ltd (WOA) and Shree Ram Agro Products, India, operating as OMN9, and its affiliates, subsidiaries and subcontractors (OMN9).	Wide Open Agriculture Ltd (WOA) and PT Haldin Pacific Semesta of Cibitung, Bekasi, West Java, Indonesia (Haldin).
Products	All products derived from the genus Lupinus.		
Binding status	Non-binding, other than the intellectual property and restraint protections described, and provisions relating to confidentiality, costs, governing law and dispute resolution. Neither party has a claim against the other if a definitive commercial agreement is not executed.		
Intellectual property	WOA retains full ownership of all intellectual property relating to lupin products, including improvements or developments made. The manufacturer may use WOA's intellectual property solely to perform its manufacturing obligations and must not reverse engineer WOA's ingredients or technology, or use WOA's processes, methods, know-how or technical information to develop, produce or supply any lupin product for itself or any third party. These protections are binding and enforceable after termination of any agreement.		
Exclusivity	VLS may not manufacture lupin-based products for itself or any other party during the term of any agreement, and for five years after its termination. Once VLS completes commercial production of more than 50 tonnes of lupin protein isolate, WOA has agreed to use VLS exclusively for its lupin manufacturing requirements for a period ending five years from the date of the agreement, provided VLS continues to accept WOA's firm purchase orders and meets production targets in line with WOA's rolling forecasts.	OMN9 may not manufacture lupin-based products for itself or any other party during the term of any agreement, and for five years after its termination.	Haldin may not manufacture any product containing lupin for itself or any other party during the term of any agreement, and for five years after its termination. WOA is not bound to use Haldin exclusively for its manufacturing requirements, or to place any minimum volume or value of orders.

Governing law	Singapore law, with disputes resolved by arbitration administered by the Singapore International Arbitration Centre (SIAC).		Western Australian law, with disputes heard in the courts of Western Australia.
Technology sharing	The parties will share technical information on process steps, equipment, production parameters and specifications, to identify capability gaps and establish the basis for trial production.		Not addressed in the term sheet. Information sharing is governed by the confidentiality provisions and will be dealt with in the definitive agreement.
Commercial terms and timing	Price, invoicing, delivery and other commercial terms will be negotiated as part of a future definitive agreement, which the parties will use best endeavours to negotiate within 90 days. This timeframe is not binding. The parties will also explore potential joint venture opportunities to manufacture large-scale commercial quantities of lupin protein, lupin fibre and lupin oil.	Price, invoicing, delivery and other commercial terms will be negotiated as part of a future definitive agreement, which the parties will use best endeavours to negotiate within 90 days. This timeframe is not binding. The parties will also discuss potential joint venture opportunities to manufacture large-scale commercial quantities of lupin protein and co-products in India.	Price, invoicing, delivery and other commercial terms will be negotiated as part of a future definitive agreement, which the parties will use best endeavours to negotiate within 90 days. This timeframe is not binding.

Next Steps

With intellectual property protection now in place each party can begin sharing detailed technical information on process steps, equipment, production parameters and specifications, building toward trial production and, potentially, a definitive commercial agreement. Next steps include developing proposed timelines for ramp-up activities and working toward alignment on key commercial terms. Each term sheet contemplates the parties using best endeavours to negotiate a definitive agreement within 90 days, although this timeframe is not binding and there is no assurance that a definitive agreement will be reached with any party.

WOA is continuing active discussions with other prospective contract manufacturing partners, and further framework agreements may be signed as part of the process of securing a final preferred manufacturing partner. WOA will only move forward with a partner well suited to its lupin protein ingredients and will provide further updates in accordance with its continuous disclosure obligations as milestones are achieved.

The Board has authorised and approved this announcement per the Company's published continuous disclosure policy.

For investors, media or other enquiries, please contact:

Craig Swan CEO , Wide Open Agriculture Ltd

craig.swan@wideopenagriculture.com.au

2/284 Oxford Street, Leederville WA 6007

About Wide Open Agriculture Ltd

Wide Open Agriculture Ltd (ASX: WOA) is a publicly listed ingredient company pioneering the development of lupin based products for the global food, beverage, cosmetics and nutraceuticals sectors. Leveraging proprietary intellectual property across its production process, WOA produces a portfolio of high-quality lupin-based plant proteins, fibres, oil and other compounds designed to enhance the functionality and performance of products across multiple sectors.

The Company's lupin-based protein isolates offer exceptional versatility across a wide range of applications, including plant-based dairy alternatives, meat substitutes, baked goods, and health-focused products. Recognised for their clean taste, high performance, and broad functionality, lupin protein isolates are emerging as an exciting new ingredient in the evolving plant-based protein market.

www.wideopenagriculture.com.au